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ABSTRACT  
Diabetes being considered as an epidemic, long term untreated complicated diabetes 
resulting in retinopathy will be a leading cause of blindness worldwide. Many cross-
sectional studies reported a strong relationship between chronic hyperglycaemia and 
development, progression of retinopathy, however the underlying mechanism that 
cause retinal microvascular damage following prolonged hyperglycaemia, yet to be 
revealed. Continued research worldwide focuses on understanding the molecular basis 
with the ultimate goal to prevent diabetic retinopathy by developing newer therapeutic 
targets. This article reviews multiple biochemical pathways that are implicated in 
diabetic retinopathy. Recent advancement in the molecular basis of the disease   as well 
as clinical trials undertaken to target these molecules in order to block the signalling 
cascade prevailing in diabetic retinopathy is also discussed. This review highlights the 
recent therapeutic targets to prevent the onset as well as the progress of retinopathy in 
diabetes. 
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INTRODUCTION 
Increased prevalence of Type-2 diabetes mellitus and insulin 
resistance (a pre diabetic condition) is a major health concern 
in India. As per International Diabetic Federation (IFD) 
estimates , the number of patients with diabetes is expected 
to be more than double by 2030.Diabetes has many 
underlying interrelated pathways that lead to potentially 
blinding complications like diabetic retinopathy.[1,2] Diabetic 
retinopathy is the most frequent microvascular complication 
of diabetes and is one of the major causes of vision loss 
worldwide. Review of population based studies revealed 
approximately 34.6% of diabetics have retinopathy.[3] Diabetic 
retinopathy occur both in type 1 and type 2 diabetes and is 
strictly related to poor glycaemic control over a prolonged 
duration of disease, however there are substantial differences 
between type 1 and type 2 diabetes in terms of clinical 
presentations and prevalence. Prevalence of retinopathy is 
more in type 1 than in type 2 diabetes and more in males than 
in female.[4] Intensive glucose control early in the course of 
the disease produced significant benefits on microvascular 
complications i.e. retinopathy  both in type1 and type2 
Diabetes mellitus.[5] In addition to the extent and duration of 
chronic hyperglycaemia , other biochemical mechanisms  like 
Polyol  accumulation, Protein Kinase C pathway, Oxidative 
damage, non-enzymatic protein glycosylation, increased 
hexosamine pathway flux as well as recently documented 
endothelium related dysfunction of the coagulant and 
anticoagulant pathway, cytokines, interleukins, Endothelin 1 
also play a role in the pathogenesis of diabetic retinopathy. All 
these pathways ultimately lead to increased oxidative stress, 
inflammation, and vascular occlusion that cause upregulation 
of factors such as vascular endothelial growth factor (VEGF), 
insulin like growth factor (IGF), stromal derived factor-1 (SDF-
1), angiopoietins (Ang-2), tumour necrosis factor (TNF), and 
basic fibroblast growth factor-2 (bFGF) leading to capillary 
damage, ischaemia with unregulated angiogenesis that is 
pathognomic of diabetic retinopathy.[6] 
Genetic studies revealed involvement of a number of genes in 
diabetic retinopathy. Aldose reductase (ALR2),receptor for 
advanced glycation end products (RAGE) ,endothelial nitric 
oxide synthase (eNOS), vascular endothelial growth factor 
(VEGF),  paraoxonase1(PON1),  plasminogen activator 
inhibitor1 (PAI) are some of the important  genes found to be 
associated with diabetic retinopathy. Polymorphisms at the 
regulatory regions of these genes have been evaluated as risk 
alleles for the progression of diabetic retinopathy.[7] According 
to the Diabetes Control and Complications Trial (DCCT)  
intensive  treatment and improved glucose control delayed 
the onset of retinopathy and slowed down its progression in 
comparison to conventional treatment.[8] Laser 
Review Article 
BIOCHEMICAL BASIS AND EMERGING MOLECULAR TARGETS TO TREAT DIABETIC 
RETINOPATHY 
*KUMARI SUCHITRA1, PANDA TARUN K2 
AUTHOR DETAILS 
1Asst. Professor, Dept. of Biochemistry, 
All India Institute of Medical Sciences   
(AIIMS), Bhubaneswar-19, Odisha. 
2Asst. professor, Dept. of 
Ophthalmology, SCB Medical College and 
Hospital, Cuttack, Odisha. 
ARTICLE INFO 
Received: 12th Dec 2015,  
Accepted: 14th Jan 2016. 
*Corresponding author email: 
suchitrakumari76@gmail.com 
Int J Clin and Biomed Res. 2016;2(1): 41-49 
42 
Kumari Suchitra et al. 
photocoagulation and Focal/grid photocoagulation have been  
effective in reducing further vision loss in diabetic 
retinopathy[9] ; however, these procedures are associated 
with potential complications.[10] To avoid these complications, 
new drugs and therapeutic targets must be identified which 
can disrupt the cascade of events underlying the 
pathogenesis of Diabetic retinopathy. So there is a need for 
better understanding of molecular basis of diabetic 
retinopathy in greater details so that newer therapeutic 
interventions can be developed for effective management. 
Biochemical mechanisms of diabetic retinopathy: 
Diabetes control and complications trial (DCCT) and United 
Kingdom Prospective Diabetes Study (UKPDS) group reported 
strong association between chronic hyperglycaemia and 
development and progression of diabetic retinopathy.[11,12] 
According to DCCT mean risk for development of any 
retinopathy was reduced by 76% in the intensive therapy 
compared to the conventional therapy. With established 
retinopathy the intensive group had a higher incidence of 
progression during the first year whereas from 3 years 
onwards, the progression of retinopathy was reduced in the 
intensive group by 54%.United Kingdom Prospective Diabetes 
Study (UKPDS) showed that patients who were assigned to 
intensive glucose control had less need for retinal 
photocoagulation .Both studies showed that glycaemic 
control is protective .Hyperglycaemia is involved in the 
pathogenesis of diabetic  retinopathy (Figure 1), nephropathy, 
neuropathy and macro vascular disease via the following 
mechanisms i.e. increased flow through the aldose-reductase 
pathway ; non enzymatic glycation and glycoxidation with 
formation of advanced glycation end products (AGEs); 
increased de-novo synthesis of diacylglycerol from glucose, 
causing protein-kinase C (PKC) activation; oxidative-
nitrosative stress with overproduction of reactive oxygen 
species (ROS).[13,14] Therefore beside the optimal glycaemic 
control , pharmacologic inhibition of these pathways might 
prevent  loss of retinal pericytes, micro aneurysm formation, 
changes in retinal hemodynamics that ultimately result in 
neovascularization a characteristic feature in diabetic 
retinopathy. 
 
Figure 1. Hyperglycaemia induced biochemical alterations 
in diabetic retinopathy 
A) Increased glucose flux through polyol pathway: 
Aldose Reductase (AR) present in the retina reduces glucose 
into sorbitol using nicotinamide adenine dinucleotide 
phosphate (NADPH) as a cofactor. Sorbitol dehydrogenase 
(SDH) with NAD+ as cofactor subsequently converts sorbitol 
into fructose. Since sorbitol is impermeable to cellular 
membranes, it accumulates within the cell and later 
metabolised to fructose.  Built up of sorbitol (Figure 2) is an 
important cause of osmotic damage to retinal cells.[15] 
Fructose  can be phosphorylated to fructose-3-phosphate 
that later can be degraded to 3-deoxyglucosone, both of 
which are strong glycating  agents and result in the production 
of Advanced Glycated End Products i.e. AGEs.[16] Increased 
utilisation  of NADPH as a cofactor in the polyol pathway 
results in less NADPH availability for use by glutathione 
reductase (enzyme involved in generation of reduced 
glutathione).Reduced glutathione being a free radical 
scavenger , its decreased level diminishes protective response 
against oxidative stress.[17] Exaggerated  NADH oxidase activity 
due to increased cytosolic NADH/NAD+ ratio by SDH results in 
increased production of reactive oxygen species(ROS) within 
retinal cells.[18] Under euglycemic conditions, hexokinase 
enzyme has higher affinity for  glucose hence  the formation 
of sorbitol is very low . However, in hyperglycaemic state 
there is a substantial increase in intracellular sorbitol levels. 
Aldose reductase has a high capacity and a low affinity for 
glucose but sorbitol dehydrogenase (SDH) has a high affinity 
and a low capacity for sorbitol. So only during hyperglycaemic 
state Aldose reductase activity is increased and sorbitol 
oxidation is relatively independent of the sorbitol 
concentration within the physiological ranges.[19,20] 
In diabetes, the sorbitol pathway activity is more in tissues like 
retina, kidney, peripheral nerves and blood vessels where 
insulin is not required for cellular glucose uptake. The polyol 
pathway seem to be an important mechanism for the 
ganglion cell apoptosis and Müller glial cell activation.[21,22] 
Aldose reductase is found in Ganglion and Müller cells of the 
retina. Since neuroglial changes may cause vascular changes 
the inhibition of the polyol pathway could also prevent the 
vascular abnormalities of diabetic retinopathy. Inhibition of 
aldose reductase was also able to prevent the early activation 
of complement in the retinal vessel wall as well as the 
apoptosis of vascular pericytes and endothelial cells and the 
development of acellularcapillaries.[23] Retinal endothelial 
cells showed aldose reductase immunoreactivity, and human 
retinas exposed to high glucose in organ culture increased the 
production of sorbitol.[24]  Experimental evidences suggest  
that defects in the polyol pathway may produce thickening of 
the capillary basement membrane, loss of mural pericytes 
and micro aneurysm  formation ,the  vascular changes 
characteristics of diabetic microangiopathy. So polyol 
pathway has been an extremely attractive target for the 
treatment of diabetic retinopathy. Animal data showed that 
aldose reductase has an early role in the pathogenesis of 
diabetic retinopathy but studies of inhibition of polyol 
pathway in vivo have yielded inconsistent results .The Sorbinil 
trial also indicated that sorbinil did not prevent the worsening 
of the disease except for a slower progression rate.[25] Animal 
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models suggest that  AR inhibitor fidarestat, is active in the 
treatment of diabetic retinopathy. Fidarestat (Figure 5) being 
an inhibitor of aldose reductase neutralizes diabetes-
associated retinal oxidative stress and  (ADP-ribose) 
polymerase formation.[26] This indicates the rationale for  the 
development of aldose reductase inhibitors for counteraction 
of polyol pathway.[27].In the streptozotocin diabetic rats, 
fidarestat treatment decreased sorbitol and fructose 
concentrations  in the  retina. Similarly in the rat model with 
retinal ischemia reperfusion injury, fidarestat treatment 
caused increased AR expression and cell death with 
decreased sorbitol pathway intermediate accumulation.[28] 
Fidarestathas a role in ICAM-1 mRNA expression  and 
leukocyte accumulation in the retina. Immunohistochemical 
study also revealed the suppressive effect of fidarestat on the 
expression of ICAM-1.[29] A double-blind study in patients with 
diabetic neuropathy documented the  efficacy of sorbinil, an 
aldose reductase inhibitor, against morphological signs of 
degeneration associated with a decrease in the nerve sorbitol 
level.[30] Zenarestat , another aldose reductase inhibitor also 
reported same results.[31] Sorbinilretinopathy trial indicated 
that sorbinil had no clinically important effect on the course 
of human diabetic retinopathy.[25] However Zenerestat had a 
positive effect on diabetic neuropathy progression[32] thus 
creating a hope in  the use of Aldose reductase inhibitors in 
diabetic retinopathy that needs further clinical trials. 
 
Figure 2. Polyol Pathway and role of Aldose reductase 
Inhibitor 
A) Non enzymatic Protein Glycosylation: 
Chronic hyperglycaemia leads  to accumulation of Advanced 
Glycation End Products (AGES) that play an important role in 
pathogenesis of  retinopathy in diabetes.[33] AGEs are  
heterogeneous molecules formed by  nonenzymatic reaction 
of  free amino groups of proteins, lipids and nucleic acids with 
the reducing sugars .    Schiff base is formed that undergoes   
spontaneously rearrangement (Maillard reaction) on itself to 
produce an Amadori adduct (Figure 3). Most glycated proteins 
are eliminated in physiological conditions, they accumulate in 
the presence of diabetes and undergo further glycation and 
molecular rearrangement that lead to the formation of 
AGEs.[34] 
Some of the AGEs in human are Carboxymethyllysine (CML), 
Carboxyethyllysine (CEL) and Pentosidine out of which CML 
have been localized to retinal blood vessels of diabetes 
patients and significant correlation has been found between 
CML and  the degree of retinopathy pointing its role in 
Diabetic retinopathy.[35] AGEs are involved in microvascular 
and macrovascular complications through the formation of 
covalent crosslinks with molecules of the basement 
membrane of the extracellular matrix and the vessel wall 
components. Binding of AGEs with a variety of cell-surface 
AGE binding receptors( receptor for advanced glycation end 
products i.e. RAGEs)  leads to cellular activation of  
prooxidant,  proinfammatory events .Various signalling 
pathways (Figure 4) that are activated by AGE receptor 
binding include tyrosine phosphorylation of Janus kinase 
(JAK)/signal transducers and activators of transcription 
(STAT)[36], recruitment of phosphatidylinositol 3 kinase to 
Ras[37], activation of protein kinase C[38] and oxidative stress by 
NFk Band AP-1 transcription[39] .CML interact with vascular 
endothelium via RAGE activating  nuclear factor kappa B (NF- 
қ B), that increase expression of adhesion molecules and 
secretion of  tumour necrosis factor alpha (TNFα) and VEGF. 
 
Figure 3. Formation of Advanced Glycation End products 
Recent investigations suggest that the AGE-RAGE interaction 
might increase VEGF gene transcription by NADPH oxidase-
mediated ROS generation and   nuclear factor- қ.B (NF-қ.B) 
activation via Ras mitogen activated protein kinase (MAPK) 
pathway.[40,41]   Knocking down of integrin-linked kinase (ILK) 
gene expression with siRNA inhibited the expression of VEGF 
and intercellular adhesion molecule 1 (ICAM-1) that indicates 
the ILK response to high glucose  and its role in pathogenesis 
of diabetic retinopathy (DR).[42,43] 
Evidences from animals studies suggest that exposure to high 
levels of AGEs cause vascular and renal complications.[44,45,46] 
Diabetic rats when treated with Aminoguanidine  
hydrochloride (AGE inhibitor), accumulation of AGE was 
significantly reduced that prevented formation of micro 
aneurysms, acellular capillaries and pericyte loss.[47] 
Treatment with vitamin B6 derivatives,  an AGE inhibitor also 
found to be protective against capillary drop out in diabetic 
rats.[44] Such observations suggest that AGE accumulation and 
its interaction with RAGE are interconnected mechanisms in 
Diabetic retinopathy and inhibition of these pathways could 
be an important therapeutic avenue.[48] Current treatments 
focus on preventing the AGE  formation, breaking established 
crosslinks and reducing receptor-ligand interactions .Recently 
Park et al. reported that  the Wnt pathway inhibitor that i.e. a 
Pigment Epithelium-Derived Factor (PEDF), a serine 
proteinase inhibitor overexpression could  attenuate Wnt 
signaling induced by retinal ischemia.[49] PEDF is also found to 
inhibit NADPH oxidase mediated ROS generation and VEGF 
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expression thus preventing AGE induced oxidative stress and 
apoptosis in retinal pericytes.[50]  Yamagishi  et al documented 
that  injection of AGEs to normal rats increases RAGE and 
ICAM-1 expression that could be prevented by  treatment 
with PEDF by inhibiting superoxide generation and NFkB 
activation in endothelial cells.[51] Aminoguanidine, a potent 
inhibitor of AGE mediated cross-linking, has been shown to 
reduce diabetic vascular complications including retinopathy 
in experimental animals.[52] 
B) Oxidative stress: 
Imbalance between the level of ROS and the antioxidant 
defence mechanisms in a biological system leads to oxidative 
stress. Hyperglycemia   induces overproduction of ROS and 
oxidative stress (Figure 4) reflected by increased 
Malondialdehyde, isoprostane, nitrotyrosine  or 8-hydroxy-2 
deoxyguanosine levels and decreased antioxidant status.[53,54] 
Reactive oxygen species are produced by glucose auto-
oxidation, protein glycation, increased flux through the polyol 
pathway, and prostanoid production. ROS and reactive 
nitrogen species (RNS) act on lipids, protein and DNA 
molecules leading to cross-link formation, lipid peroxidation 
and protein modification.  Pericytes are highly sensitive to the 
oxidative stress and increased rate of apoptosis due to 
decreased level of antioxidant enzymes.[55] Progressive 
Pericyte loss leads to pore formation in the blood vessel wall 
thus proteins are leaked , a characteristic finding in non 
proliferative diabetic retinopathy i.e. hard exudates. 
 
Figure 4.  Interrelationship of Biochemical Mechanisms in 
diabetic retinopathy 
Animal studies documented that oxidative stress cause 
development of retinopathy in diabetes and it prevent 
retinopathy to reverse even after euglycemic state is 
achieved.[56] In diabetes the antioxidant enzymes i.e. SOD, 
glutathione reductase, glutathione peroxidase, catalase are 
found decreased in the retina.[57] It is also reported that type 
2 diabetes mellitus is associated with reduced plasma total 
antioxidant status and increased plasma oxidisability with 
reduced plasma ascorbic acid and vitamin E.[58] Lipoicacid  
scavenge ROS and reduces glutathione to maintain a healthy 
cellular redox state.[59] Lipoic acid supplementation prevents 
diabetes-induced increase in nitrotyrosine and activation of 
NF-қB , decrease VEGF and oxidatively modified proteins in 
the rat retina.[60] Vitamin E through non enzymatic 
mechanisms act as free radical scavenger in DR.[61] Trolox  
prevent the loss of pericytes in diabetic rats[62] Carotenoid, 
lutein and zeaxanthin prevented progression of DR and 
maintained normal retinal function, mitochondrial 
homeostasis and inflammatory mediators.[63] 
C)  Protein Kinase C pathway: 
Protein kinase C (PKC) is a family of 10 enzymes, in which the 
β 1/2 isoforms are closely associated with the development 
of diabetic retinopathy.[64] So far 12 PKC isoforms have been 
isolated and can be divided into 3 groups i.e. classical, novel 
and typical. Classical isoform (PKC-α,β ½,δ) are enhanced by 
Diacylglycerol (DAG) and have been linked to vascular 
dysfunction and pathogenesis of DR.[65] Hyperglycaemia 
increase glucose flux through the  glycolytic pathway, which 
increases DAG , the key activator of PKC.[66] activation of PKC 
has a cascade-like effect on several other pathways that 
influence  endothelial permeability, retinal hemodynamic, 
and expression of vascular endothelial growth factor (VEGF) 
in the retinal along with  leukocyte adhesion.[67,68] 
Upregulation of PKC contribute  to the pathogenesis of 
diabetic retinopathy i.e. extracellular matrix (ECM) 
remodelling, differential synthesis of extra cellular matrix  
proteins, release of angiogenic factors, endothelial and 
leukocyte dysfunction leading to vascular changes pertaining 
to DR.[69] 
PKC   inhibitors are new potential therapeutics useful in DR. 
They can delay the onset or prevent   the progression of 
vascular complications of diabetes. Isoquinoline 
sulphonamides and staurosporine the first and second 
generation PKC inhibitors are of therapeutic interest.[70,71,72,73] 
Ruboxistaurin mesylate was  reported in science.[74] Vitamin E  
can inhibit PKC activity by decreasing DAG contents by  
activation of DAG kinase.[75,61] PKC β inhibitor  Ruboxistaurin 
(Figure 5) reduces the mitogenic response to VEGF, in contrast 
with PKC-α  inhibition.[76] Selective inhibition is very crucial to 
develop clinically safe therapeutic PKC inhibitors. Tuttle et al 
documented that PKC isoform selective inhibitors can be used 
for chronic clinical   treatment with nominal side effects.[77] So, 
selective PKC inhibitors are likely  new potential therapeutics 
in DR. Endothelium related dysfunction of the coagulant and 
anticoagulant pathway has been documented in diabetes.[78] 
D) Miscellaneous Mechanisms: 
 In case of proliferative diabetic retinopathy a 
hypercoagulable state is present due to conversion of the 
endothelium from a thermoresistant   to a thermogenic 
surface with activation of extrinsic haemostatic pathway. 
Moreover finding of anti-pericyte and phospholipid binding 
autoantibodies (eg. Leupus anticoagulants) as  well as 
presence of T lymphocytes, B lymphocytes , HLA DR/DQ 
expressing cells ,macrophages  and Ig deposits in the 
vitreous and the pre retinal membrane suggest 
immunological basis of diabetic retinopathy.[79,80] 
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Figure 5.  Biochemical   basis and emerging molecular 
targets 
 A number of growth factors have been associated with the 
development of Diabetic Retinopathy.[81,82] Basic fibroblast 
growth factor (b FGF).[83] Insulin like growth factor 1(IGF-
1).[84] Angiopoitin 1 and 2[85,86], stromal derived factor 1 
87 ,Epidermal growth factor(EGF)[88], Transforming growth 
factor β 2(TGF- β 2)[89], Platelet derived growth factor[90] and 
Erythropoitin91 have been found associated with DR. 
  Anti VEGF agents are recently developed as a treatment 
modality in DR. Pegaptenib, Ranibizumab, Bevacizumab are 
some of the current anti VEGF agents.[92-95] Recent advances 
suggest cautious use of anti VEGF agents on long term basis 
to treat DR due to the fact that VEGF has a role as retinal 
neuron survival factor and its inhibition may lead to 
destruction of cells  i.e. photoreceptors, muller glia  that are 
involved in visual function.[96] 
 Many studies highlighted the importance of subclinical 
inflammation in the development of DR.[97-99] 
Hyperglycaemia , hypertension, oxidative stress ,Advanced 
Glycation End products all contribute to inflammation and 
inflammatory response in tern regulates these pathways via 
cytokines, VEGF signalling, adhesion molecules, Enhanced 
RAGE expression, NFkB signalling. Leucostasis is another 
hallmark in the pathogenesis of DR as it causes capillary 
occlusion, ROS mediated cell death that enhance 
inflammatory response locally in retinal tissues.[100] 
Therefore subclinical inflammation in the retina leads to 
increased intra ocular pressure, formation of new, weak 
vessels and their increased permeability due to VEGF that 
cause retinal haemorrhage. Activation of microglia and 
immune cells is also revealed by many researchers.[101] This 
fact has been supported by the use of Minocyclin, an 
antibiotic and anti-inflammatory agent  that block the 
activation of Microglia and prevent DR.[102] The use of 
intravitreal  Triamcinolone acetonide and non-steroidal 
anti-inflammatory drugs i.e. Nepafenac has been reported 
to reduce VEGF expression, normalize vascular 
permeability and reduce apoptosis , leucostasis that 
improve visual acuity.[103,104] There is also great deal of 
interest in intraocular implants that deliver anti- 
inflammatory steroids.[105,106] 
 A significant relationship between VEGF and IL-6 was 
reported by Funatsu et al. Aqueous levels of these two 
parameters were correlated with the severity of fundus 
findings.[107] Recently VEGF & IL-6 relationship & their   
levels in vitreous fluid has been documented[108,109] thus 
pointing towards the usefulness of their measurement as 
an analytical marker of pathogenesis of DR and to predict 
the progression of retinal diseases.  
 Matrix Metalloproteinases (MMP) 2.9 and their tissue 
inhibitors (TIMP) were found elevated in vitreous of 
diabetic patients and were correlated with severity of 
retinopathy.[110, 111] MMP activity represent the “ final 
common pathway” in retinal neovascularisation from 
whatever cause and therapeutic inhibition at this level may 
be more effective then targeting individual pathway.  
 Endothelin-1 (ET-1) is a peptide produced by the 
endothelial cells that induces vasoconstriction. Studies 
reported that hypoxia induces ET-1 gene expression in 
endothelial cells.[112] A position association between ET-1 
expression and PKC activation in early diabetes reflected 
the fact that PKC inhibitors could be able to reverse the 
upregulation of ET-1.[113] Therapeutic effect of long-term 
selective blockade of endothelin A (ETA) receptor has been 
recently evaluated in a genetic mouse model of non obese 
type-1 diabetes.[114] Such studies suggest a new strategy for 
preventing development of retinopathy in diabetes. 
Fenofibrate (Peroxisome   proliferator activated  receptor  
PPAR-α agonist) is used  to treat high triglycerides and low 
HDL or as adjunct to statin therapy. It regulates the expression 
of many genes that work against lipids, inflammation, 
angiogenesis, and cell apoptosis. The ACCORD Eye Study 
group involved a subset of 2,856 participants reported that 
the rates of progression of diabetic retinopathy were 
significantly reduced in the intensive glycemic control group 
and in the fenofibrate group.[115] 
CONCLUSION 
The pathogenesis of DR is very complex and many 
biochemical mechanisms have been proposed which are 
interactive and interdependent. This review provides better 
understanding of complex biochemical mechanisms and 
treatment modalities of recent Interest. At proliferative 
phase of retinopathy therapeutic interventions are effective 
but in advanced stage hypoxia induced VEGF production 
leads to disease progression. Overexpression of growth 
factors i.e. VEGF, IGF-1, stromal derived GF-1, angiopoetin- 1 
& 2, fibroblast Growth Factor act in synergy in mediating 
process of angiogenesis and  endothelial are proliferation. As 
there is a complex interplay between the biochemical   
pathways, understanding the molecular basis of these 
pathways in greater details will help in exploring newer 
pharmacological agents targeted to block different pathways 
that could provide a better insight in preventing the disease 
progression in Diabetic Retinopathy. 
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